relation,display_relation,x_index,x_id,x_type,x_name,x_source,y_index,y_id,y_type,y_name,y_source,source_type,source_link,source_date
disease_phenotype_positive,phenotype present,28310,7433,disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,MONDO,23153,1300,effect/phenotype,Parkinsonism,HPO,,,
disease_phenotype_positive,phenotype present,28310,7433,disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,MONDO,22442,726,effect/phenotype,Dementia,HPO,,,
disease_phenotype_positive,phenotype present,28310,7433,disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,MONDO,89049,11960,effect/phenotype,Substantia nigra gliosis,HPO,,,
disease_phenotype_positive,phenotype present,28310,7433,disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,MONDO,22759,6,effect/phenotype,Autosomal dominant inheritance,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22999,2015,effect/phenotype,Dysphagia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,91412,31868,effect/phenotype,Optic ataxia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22998,1288,effect/phenotype,Gait disturbance,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,24284,2354,effect/phenotype,Memory impairment,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85516,3487,effect/phenotype,Babinski sign,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23000,1250,effect/phenotype,Seizure,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,24262,2120,effect/phenotype,Cerebral cortical atrophy,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22421,2186,effect/phenotype,Apraxia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,24294,2395,effect/phenotype,Lower limb hyperreflexia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23135,1260,effect/phenotype,Dysarthria,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84858,1285,effect/phenotype,Spastic tetraparesis,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23515,3581,effect/phenotype,Adult onset,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85078,2185,effect/phenotype,Neurofibrillary tangles,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22692,2071,effect/phenotype,Abnormality of extrapyramidal motor function,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33758,10524,effect/phenotype,Agnosia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22442,726,effect/phenotype,Dementia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84708,751,effect/phenotype,Personality changes,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22759,6,effect/phenotype,Autosomal dominant inheritance,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23545,1336,effect/phenotype,Myoclonus,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85588,3678,effect/phenotype,Rapidly progressive,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23153,1300,effect/phenotype,Parkinsonism,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,93704,410054,effect/phenotype,Decreased level of GABA in serum,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85153,2423,effect/phenotype,Long-tract signs,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84887,1425,effect/phenotype,Heterogeneous,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,26293,6979,effect/phenotype,Sleep-wake cycle disturbance,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85562,3596,effect/phenotype,Middle age onset,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22682,100543,effect/phenotype,Cognitive impairment,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,89468,12662,effect/phenotype,Parietal hypometabolism in FDG PET,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,94248,11970,effect/phenotype,Cerebral amyloid angiopathy,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,27073,100256,effect/phenotype,Senile plaques,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84695,716,effect/phenotype,Depressivity,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,26205,734,effect/phenotype,Disinhibition,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,26653,410170,effect/phenotype,Hippocampal atrophy,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85559,3584,effect/phenotype,Late onset,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22454,2167,effect/phenotype,Neurological speech impairment,HPO,,,
disease_phenotype_positive,phenotype present,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,23000,1250,effect/phenotype,Seizure,HPO,,,
disease_phenotype_positive,phenotype present,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,86805,6790,effect/phenotype,Cerebral cortex with spongiform changes,HPO,,,
disease_phenotype_positive,phenotype present,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,85078,2185,effect/phenotype,Neurofibrillary tangles,HPO,,,
disease_phenotype_positive,phenotype present,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,27073,100256,effect/phenotype,Senile plaques,HPO,,,
disease_phenotype_positive,phenotype present,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,22759,6,effect/phenotype,Autosomal dominant inheritance,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,22398,708,effect/phenotype,Behavioral abnormality,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,84693,712,effect/phenotype,Emotional lability,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,84695,716,effect/phenotype,Depressivity,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,22447,739,effect/phenotype,Anxiety,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,25254,1328,effect/phenotype,Specific learning disability,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,22679,2360,effect/phenotype,Sleep disturbance,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,85185,2549,effect/phenotype,Deficit in phonologic short-term memory,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,86892,7018,effect/phenotype,Attention deficit hyperactivity disorder,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,22979,11458,effect/phenotype,Abdominal symptom,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,26199,30223,effect/phenotype,Perseveration,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,92920,40264,effect/phenotype,Jaw pain,HPO,,,
disease_phenotype_positive,phenotype present,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,22682,100543,effect/phenotype,Cognitive impairment,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84694,713,effect/phenotype,Agitation,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23113,738,effect/phenotype,Hallucinations,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22676,1276,effect/phenotype,Hypertonia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,26162,1289,effect/phenotype,Confusion,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,85633,3791,effect/phenotype,Deposits immunoreactive to beta-amyloid protein,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22445,12433,effect/phenotype,Abnormal social behavior,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22670,12759,effect/phenotype,Neurodevelopmental abnormality,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22343,504,effect/phenotype,Abnormality of vision,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,84678,657,effect/phenotype,Oculomotor apraxia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22675,1249,effect/phenotype,Intellectual disability,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22699,1251,effect/phenotype,Ataxia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,23125,2381,effect/phenotype,Aphasia,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22671,11446,effect/phenotype,Abnormality of higher mental function,HPO,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,90327,30219,effect/phenotype,Semantic dementia,HPO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,94982,10783,disease,"Alzheimer disease, susceptibility to, mitochondrial",MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,,,
disease_disease,parent-child,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20294,DB11160,drug,Phenyltoloxamine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16490,DB01620,drug,Pheniramine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15147,DB01173,drug,Orphenadrine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17407,DB00175,drug,Pravastatin,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15832,DB00395,drug,Carisoprodol,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16350,DB04272,drug,Citric acid,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17062,DB00241,drug,Butalbital,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15089,DB00318,drug,Codeine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14182,DB00497,drug,Oxycodone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20303,DB13719,drug,Trolnitrate,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20304,DB08797,drug,Salicylamide,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15181,DB03783,drug,Phenacetin,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14881,DB00388,drug,Phenylephrine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16550,DB00975,drug,Dipyridamole,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14783,DB00201,drug,Caffeine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17064,DB00371,drug,Meprobamate,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16790,DB00423,drug,Methocarbamol,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14993,DB01174,drug,Phenobarbital,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15112,DB00647,drug,Dextropropoxyphene,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16506,DB00652,drug,Pentazocine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20311,DB11126,drug,Calcium gluconate,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14898,DB00397,drug,Phenylpropanolamine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14990,DB01114,drug,Chlorpheniramine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15132,DB00956,drug,Hydrocodone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15171,DB01551,drug,Dihydrocodeine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20185,DB11275,drug,Epicriptine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20300,DB12710,drug,Perazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17243,DB01246,drug,Alimemazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16071,DB01625,drug,Isopropamide,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16317,DB01618,drug,Molindone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15110,DB00623,drug,Fluphenazine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20523,DB13247,drug,Pramiracetam,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15165,DB01403,drug,Methotrimeprazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15098,DB00420,drug,Promazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15127,DB00850,drug,Perphenazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15100,DB00433,drug,Prochlorperazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15093,DB00363,drug,Clozapine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14176,DB00472,drug,Fluoxetine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14952,DB00502,drug,Haloperidol,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14178,DB00477,drug,Chlorpromazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15114,DB00679,drug,Thioridazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14156,DB00321,drug,Amitriptyline,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17234,DB00777,drug,Propiomazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14351,DB01623,drug,Thiothixene,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20211,DB08842,drug,Acetylcarnitine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16434,DB01063,drug,Acetophenazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14988,DB01100,drug,Pimozide,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16011,DB00408,drug,Loxapine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14140,DB00246,drug,Ziprasidone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14841,DB00508,drug,Triflupromazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15001,DB01267,drug,Paliperidone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15006,DB04946,drug,Iloperidone,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14161,DB00334,drug,Olanzapine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14323,DB01238,drug,Aripiprazole,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14913,DB00831,drug,Trifluoperazine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,16014,DB01239,drug,Chlorprothixene,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14999,DB01224,drug,Quetiapine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14223,DB00734,drug,Risperidone,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO_grouped,20185,DB11275,drug,Epicriptine,DrugBank,,,
contraindication,contraindication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,14380,DB06216,drug,Asenapine,DrugBank,,,
contraindication,contraindication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,14380,DB06216,drug,Asenapine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,20575,DB13668,drug,Ipidacrine,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,20575,DB13668,drug,Ipidacrine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15113,DB00674,drug,Galantamine,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,15113,DB00674,drug,Galantamine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15294,DB00382,drug,Tacrine,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,15294,DB00382,drug,Tacrine,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,20211,DB08842,drug,Acetylcarnitine,DrugBank,,,
contraindication,contraindication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,14323,DB01238,drug,Aripiprazole,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,17174,DB00989,drug,Rivastigmine,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,17174,DB00989,drug,Rivastigmine,DrugBank,,,
indication,indication,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,15126,DB00843,drug,Donepezil,DrugBank,,,
indication,indication,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,15126,DB00843,drug,Donepezil,DrugBank,,,
disease_phenotype_positive,phenotype present,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,22996,2011,effect/phenotype,Morphological central nervous system abnormality,HPO,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1048,2,gene/protein,A2M,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1048,2,gene/protein,A2M,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8038,43,gene/protein,ACHE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8038,43,gene/protein,ACHE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,7717,102,gene/protein,ADAM10,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,7717,102,gene/protein,ADAM10,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,397,267,gene/protein,AMFR,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,397,267,gene/protein,AMFR,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1762,274,gene/protein,BIN1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1762,274,gene/protein,BIN1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2606,341,gene/protein,APOC1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2606,341,gene/protein,APOC1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3879,348,gene/protein,APOE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3879,348,gene/protein,APOE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,611,351,gene/protein,APP,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,611,351,gene/protein,APP,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,854,498,gene/protein,ATP5F1A,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,854,498,gene/protein,ATP5F1A,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1139,581,gene/protein,BAX,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1139,581,gene/protein,BAX,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,341,590,gene/protein,BCHE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,341,590,gene/protein,BCHE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2429,596,gene/protein,BCL2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2429,596,gene/protein,BCL2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6329,627,gene/protein,BDNF,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6329,627,gene/protein,BDNF,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61,801,gene/protein,CALM1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,61,801,gene/protein,CALM1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2712,836,gene/protein,CASP3,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2712,836,gene/protein,CASP3,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1045,945,gene/protein,CD33,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1045,945,gene/protein,CD33,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,13566,1139,gene/protein,CHRNA7,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,13566,1139,gene/protein,CHRNA7,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8317,1141,gene/protein,CHRNB2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8317,1141,gene/protein,CHRNB2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1127,1191,gene/protein,CLU,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1127,1191,gene/protein,CLU,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4352,1200,gene/protein,TPP1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4352,1200,gene/protein,TPP1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,12122,1378,gene/protein,CR1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,12122,1378,gene/protein,CR1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,9021,1392,gene/protein,CRH,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,9021,1392,gene/protein,CRH,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,5080,1471,gene/protein,CST3,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,5080,1471,gene/protein,CST3,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,13807,1565,gene/protein,CYP2D6,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,13807,1565,gene/protein,CYP2D6,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,13097,1636,gene/protein,ACE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,13097,1636,gene/protein,ACE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8712,1718,gene/protein,DHCR24,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8712,1718,gene/protein,DHCR24,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3111,1808,gene/protein,DPYSL2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3111,1808,gene/protein,DPYSL2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3316,1965,gene/protein,EIF2S1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3316,1965,gene/protein,EIF2S1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3434,2023,gene/protein,ENO1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3434,2023,gene/protein,ENO1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,228,2041,gene/protein,EPHA1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,228,2041,gene/protein,EPHA1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,375,2099,gene/protein,ESR1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,375,2099,gene/protein,ESR1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,29,2147,gene/protein,F2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,29,2147,gene/protein,F2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33,2932,gene/protein,GSK3B,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33,2932,gene/protein,GSK3B,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8855,3077,gene/protein,HFE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8855,3077,gene/protein,HFE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8021,3127,gene/protein,HLA-DRB5,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8021,3127,gene/protein,HLA-DRB5,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3192,3162,gene/protein,HMOX1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3192,3162,gene/protein,HMOX1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4596,3416,gene/protein,IDE,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4596,3416,gene/protein,IDE,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,5720,3479,gene/protein,IGF1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,5720,3479,gene/protein,IGF1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1066,3480,gene/protein,IGF1R,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1066,3480,gene/protein,IGF1R,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4550,3481,gene/protein,IGF2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4550,3481,gene/protein,IGF2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2114,3482,gene/protein,IGF2R,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2114,3482,gene/protein,IGF2R,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1004,3553,gene/protein,IL1B,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1004,3553,gene/protein,IL1B,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,213,3630,gene/protein,INS,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,213,3630,gene/protein,INS,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2760,3635,gene/protein,INPP5D,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2760,3635,gene/protein,INPP5D,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4536,3643,gene/protein,INSR,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4536,3643,gene/protein,INSR,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,11523,3952,gene/protein,LEP,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,11523,3952,gene/protein,LEP,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,8192,4129,gene/protein,MAOB,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,8192,4129,gene/protein,MAOB,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2915,4137,gene/protein,MAPT,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2915,4137,gene/protein,MAPT,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4818,4353,gene/protein,MPO,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4818,4353,gene/protein,MPO,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6175,4524,gene/protein,MTHFR,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6175,4524,gene/protein,MTHFR,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4497,4846,gene/protein,NOS3,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4497,4846,gene/protein,NOS3,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,10835,4852,gene/protein,NPY,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,10835,4852,gene/protein,NPY,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,5137,5328,gene/protein,PLAU,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,5137,5328,gene/protein,PLAU,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,7569,5336,gene/protein,PLCG2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,7569,5336,gene/protein,PLCG2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,989,5468,gene/protein,PPARG,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,989,5468,gene/protein,PPARG,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6940,5621,gene/protein,PRNP,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6940,5621,gene/protein,PRNP,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6195,5649,gene/protein,RELN,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6195,5649,gene/protein,RELN,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,743,5663,gene/protein,PSEN1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,743,5663,gene/protein,PSEN1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,702,5664,gene/protein,PSEN2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,702,5664,gene/protein,PSEN2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,11482,5697,gene/protein,PYY,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,11482,5697,gene/protein,PYY,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4278,5819,gene/protein,NECTIN2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4278,5819,gene/protein,NECTIN2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,5508,6517,gene/protein,SLC2A4,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,5508,6517,gene/protein,SLC2A4,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4959,6648,gene/protein,SOD2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4959,6648,gene/protein,SOD2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4890,6653,gene/protein,SORL1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4890,6653,gene/protein,SORL1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4003,7018,gene/protein,TF,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4003,7018,gene/protein,TF,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6751,7019,gene/protein,TFAM,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6751,7019,gene/protein,TFAM,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2329,7124,gene/protein,TNF,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2329,7124,gene/protein,TNF,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,7621,7167,gene/protein,TPI1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,7621,7167,gene/protein,TPI1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,749,7422,gene/protein,VEGFA,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,749,7422,gene/protein,VEGFA,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6821,7447,gene/protein,VSNL1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6821,7447,gene/protein,VSNL1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1491,7782,gene/protein,SLC30A4,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1491,7782,gene/protein,SLC30A4,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,4378,8301,gene/protein,PICALM,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,4378,8301,gene/protein,PICALM,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33778,8633,gene/protein,UNC5C,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33778,8633,gene/protein,UNC5C,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,9689,9510,gene/protein,ADAMTS1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,9689,9510,gene/protein,ADAMTS1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,12825,10347,gene/protein,ABCA7,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,12825,10347,gene/protein,ABCA7,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,2665,10452,gene/protein,TOMM40,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,2665,10452,gene/protein,TOMM40,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,7474,10857,gene/protein,PGRMC1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,7474,10857,gene/protein,PGRMC1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,12321,10858,gene/protein,CYP46A1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,12321,10858,gene/protein,CYP46A1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,983,23237,gene/protein,ARC,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,983,23237,gene/protein,ARC,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,216,23385,gene/protein,NCSTN,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,216,23385,gene/protein,NCSTN,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1820,23607,gene/protein,CD2AP,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1820,23607,gene/protein,CD2AP,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,6043,23621,gene/protein,BACE1,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,6043,23621,gene/protein,BACE1,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,1031,26330,gene/protein,GAPDHS,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,1031,26330,gene/protein,GAPDHS,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33881,27328,gene/protein,PCDH11X,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33881,27328,gene/protein,PCDH11X,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,3837,51225,gene/protein,ABI3,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,3837,51225,gene/protein,ABI3,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,9852,51338,gene/protein,MS4A4A,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,9852,51338,gene/protein,MS4A4A,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,602,51741,gene/protein,WWOX,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,602,51741,gene/protein,WWOX,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33882,54209,gene/protein,TREM2,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33882,54209,gene/protein,TREM2,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,12188,55676,gene/protein,SLC30A6,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,12188,55676,gene/protein,SLC30A6,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,11770,57091,gene/protein,CASS4,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,11770,57091,gene/protein,CASS4,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33883,124152,gene/protein,IQCK,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33883,124152,gene/protein,IQCK,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33884,406892,gene/protein,MIR100,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33884,406892,gene/protein,MIR100,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33885,406938,gene/protein,MIR146A,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33885,406938,gene/protein,MIR146A,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33886,407022,gene/protein,MIR296,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33886,407022,gene/protein,MIR296,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33887,494324,gene/protein,MIR375,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33887,494324,gene/protein,MIR375,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33888,574508,gene/protein,MIR505,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33888,574508,gene/protein,MIR505,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33889,768218,gene/protein,MIR766,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33889,768218,gene/protein,MIR766,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33890,100126333,gene/protein,MIR708,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33890,100126333,gene/protein,MIR708,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33891,100170222,gene/protein,SNAR-I,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33891,100170222,gene/protein,SNAR-I,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33892,100500871,gene/protein,MIR3622B,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33892,100500871,gene/protein,MIR3622B,NCBI,,,
disease_protein,associated with,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,33893,100616367,gene/protein,MIR4467,NCBI,,,
disease_protein,associated with,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,33893,100616367,gene/protein,MIR4467,NCBI,,,
disease_protein,associated with,94982,10783,disease,"Alzheimer disease, susceptibility to, mitochondrial",MONDO,34591,4535,gene/protein,ND1,NCBI,,,
disease_protein,associated with,94982,10783,disease,"Alzheimer disease, susceptibility to, mitochondrial",MONDO,35239,4536,gene/protein,ND2,NCBI,,,
disease_protein,associated with,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,6940,5621,gene/protein,PRNP,NCBI,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,37652,5574,disease,tauopathy,MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,37573,1627,disease,dementia (disease),MONDO,,,
disease_disease,parent-child,28310,7433,disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,MONDO,35432,3847,disease,Mendelian disease,MONDO,,,
disease_disease,parent-child,94982,10783,disease,"Alzheimer disease, susceptibility to, mitochondrial",MONDO,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,
disease_disease,parent-child,83960,11401,disease,Alzheimer disease without neurofibrillary tangles,MONDO,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,
disease_disease,parent-child,31527,11513,disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",MONDO,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,35439,20573,disease,inherited disease susceptibility,MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,35655,426,disease,autosomal dominant disease,MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,35480,24237,disease,inherited neurodegenerative disorder,MONDO,,,
disease_disease,parent-child,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,38241,15547,disease,genetic dementia,MONDO,,,
disease_disease,parent-child,32654,17233_100087,disease,familial Alzheimer disease,MONDO_grouped,38228,17234,disease,inherited prion disease,MONDO,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61882,D000535,exposure,Aluminum,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61717,D002104,exposure,Cadmium,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61761,D008670,exposure,Metals,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61777,D009589,exposure,Nitrogen Oxides,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61782,D010126,exposure,Ozone,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61785,D052638,exposure,Particulate Matter,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61796,D010575,exposure,Pesticides,CTD,,,
exposure_disease,linked to,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,61807,D012822,exposure,Silicon Dioxide,CTD,,,
pathway_pathway,parent-child,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,62932,R-HSA-8863678,pathway,Neurodegenerative Diseases,REACTOME,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,4295,10018,gene/protein,BCL2L11,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,985,1020,gene/protein,CDK5,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,1479,2309,gene/protein,FOXO3,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,701,2801,gene/protein,GOLGA2,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,611,351,gene/protein,APP,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,4676,356,gene/protein,FASLG,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,326,3725,gene/protein,JUN,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,163,4000,gene/protein,LMNA,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,1126,4001,gene/protein,LMNB1,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,1783,5052,gene/protein,PRDX1,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,4959,6648,gene/protein,SOD2,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,3931,7001,gene/protein,PRDX2,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,1806,7531,gene/protein,YWHAE,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,2491,823,gene/protein,CAPN1,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,8357,824,gene/protein,CAPN2,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,3252,826,gene/protein,CAPNS1,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,7957,831,gene/protein,CAST,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,9507,84290,gene/protein,CAPNS2,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,4892,8851,gene/protein,CDK5R1,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,6823,993,gene/protein,CDC25A,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,336,994,gene/protein,CDC25B,NCBI,,,
pathway_protein,interacts with,129024,R-HSA-8862803,pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,REACTOME,2994,995,gene/protein,CDC25C,NCBI,,,
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Mild (MMSE 21-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Moderate (MMSE 10-20),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Severe (MMSE <10),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Phenotypes,Memory loss for recent events,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Phenotypes,Difficulty learning new information,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Phenotypes,Subtle language problems,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Phenotypes,Significant memory loss,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Phenotypes,Confusion in daily activities,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Phenotypes,Behavioral changes,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Phenotypes,Severe memory loss,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Phenotypes,Complete dependence on others,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Phenotypes,Physical symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Donepezil Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Donepezil Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Galantamine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Donepezil Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Donepezil Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (NICE),,,,Evidence,Moderate quality (Level B),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Patch Treatment (NICE),,,,Evidence,Moderate quality (Level B),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment (NICE),,,,Evidence,Moderate quality (Level B),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment moderate hepatic impairment (NICE),,,,Evidence,Moderate quality (Level B),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment renal impairment 1 (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment renal impairment 2 (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment renal impairment 3 (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Haloperidol Treatment (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Risperidone Treatment (NICE),,,,Evidence,High quality (Level A),,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023-01-15
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (NICE),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_STEP,,,,Treatment,Donepezil Treatment (NICE),,,,Step,Donepezil Treatment (NICE) (1),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (NICE) (1),,,,Dosage,Donepezil 5mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Donepezil 5mg/day,,,,Duration,1 month,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Donepezil Treatment (NICE) (1),,,,Step,Donepezil Treatment (NICE) (2),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (NICE) (2),,,,Dosage,Donepezil 10mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_POPULATION,,,,Step,Donepezil Treatment (NICE) (2),,,,Population,increased if tolerated and necessary,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Donepezil Treatment (NICE),,,,Effectiveness,Significant improvement in cognitive scores and daily activities,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (NICE),,,,Population,Mild to Severe Alzheimer's Disease (MMSE 0-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Galantamine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (NICE),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_STEP,,,,Treatment,Galantamine Treatment (NICE),,,,Step,Galantamine Treatment (NICE) (1),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Galantamine Treatment (NICE) (1),,,,Dosage,Galantamine 8mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8mg/day,,,,Duration,4 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Galantamine Treatment (NICE) (1),,,,Step,Galantamine Treatment (NICE) (2),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Galantamine Treatment (NICE) (2),,,,Dosage,Galantamine 16mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Galantamine 16mg/day,,,,Duration,least 4 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Galantamine Treatment (NICE) (2),,,,Step,Galantamine Treatment (NICE) (3),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Galantamine Treatment (NICE) (3),,,,Dosage,Galantamine 16-24mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (NICE),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment moderate hepatic impairment (NICE),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_STEP,,,,Treatment,Galantamine Treatment moderate hepatic impairment (NICE),,,,Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),,,,Dosage,Galantamine 8mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8mg/day,,,,Duration,1 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),,,,Step,Galantamine Treatment moderate hepatic impairment (NICE) (2),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Galantamine Treatment moderate hepatic impairment (NICE) (2),,,,Dosage,Galantamine 8-16mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8-16mg/day,,,,Duration,4 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment moderate hepatic impairment (NICE),,,,Population,moderate hepatic impairment,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment moderate hepatic impairment (NICE),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (NICE),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (NICE),,,,Dosage,Rivastigmine 1.5-6.0 twice daily,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (NICE),,,,Population,Mild to Severe Alzheimer's Disease (MMSE 0-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Patch Treatment (NICE),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_STEP,,,,Treatment,Rivastigmine Patch Treatment (NICE),,,,Step,Rivastigmine Patch Treatment (NICE) (1),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (NICE) (1),,,,Dosage,Rivastigmine Patch 4.6mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 4.6mg/day,,,,Duration,4 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Rivastigmine Patch Treatment (NICE) (1),,,,Step,Rivastigmine Patch Treatment (NICE) (2),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (NICE) (2),,,,Dosage,Rivastigmine Patch 9.5mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 9.5mg/day,,,,Duration,6 week,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_STEP,,,,Step,Rivastigmine Patch Treatment (NICE) (2),,,,Step,Rivastigmine Patch Treatment (NICE) (3),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (NICE) (3),,,,Dosage,Rivastigmine Patch 13.3mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Patch Treatment (NICE),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (NICE),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment (NICE),,,,Dosage,Memantine 5-20 mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment (NICE),,,,Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (NICE),,,,Population,Moderate to severe Alzheimer's Disease (MMSE < 20),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment renal impairment 1 (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment renal impairment 1 (NICE),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment renal impairment 1 (NICE),,,,Dosage,Memantine 10-20 mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment renal impairment 1 (NICE),,,,Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment renal impairment 1 (NICE),,,,Population,eGFR is 30–49 mL/minute/1.73 m²,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment renal impairment 2 (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment renal impairment 2 (NICE),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment renal impairment 2 (NICE),,,,Dosage,Memantine 10 mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment renal impairment 2 (NICE),,,,Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment renal impairment 2 (NICE),,,,Population,eGFR is 5 - 29 mL/minute/1.73 m²,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Haloperidol Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Haloperidol Treatment (NICE),Guideline,14952,DB00502,drug,Haloperidol,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Haloperidol Treatment (NICE),,,,Dosage,Haloperidol 0.5-5 mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Haloperidol Treatment (NICE),,,,Duration,no more than 6 weeks,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Risperidone Treatment (NICE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_TREATMENT,,,,Treatment,Risperidone Treatment (NICE),Guideline,14223,DB00734,drug,Risperidone,DrugBank,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
TREATMENT_DOSAGE,,,,Treatment,Risperidone Treatment (NICE),,,,Dosage,Risperidone 0.5-5 mg/day,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DOSAGE_DURATION,,,,Dosage,Risperidone 0.5-5 mg/day,,,,Duration,no more than 6 weeks,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Nausea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Vomiting,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Anorexia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Muscle cramps,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Syncope,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Headache,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Dizziness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Abnormal dreams,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Hallucinations,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Agitation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Aggression,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Urinary incontinence,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rash,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Pruritus,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Extrapyramidal symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Sinoatrial block,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Atrioventricular (AV) block,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Liver dysfunction (including hepatitis),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Neuroleptic malignant syndrome (NMS),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Fatigue,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Insomnia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Nausea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Abdominal pain,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Diarrhoea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dyspepsia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Decreased appetite,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Weight loss ,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Bradycardia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Hypertension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Syncope,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Hallucinations,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Depression,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Tremor,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Headache,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Fatigue,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Malaise,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Muscle spasm,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Retching,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dehydration,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Hypotension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Flushing,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Palpitation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Arrhythmias,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,First-degree AV block,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Taste disturbance,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Paraesthesia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Seizures,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Hypersomnia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Muscular weakness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Blurred vision,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Tinnitus,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Sweating,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Exacerbation of Parkinson's disease,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Hepatitis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Serious skin reactions,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Nausea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Diarrhoea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Dyspepsia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Anorexia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Weight loss,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Abdominal pain,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Bradycardia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Headache,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Drowsiness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Gait abnormalities,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Fall,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Malaise,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Agitation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Anxiety,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Tremor,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Confusion,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Insomnia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Parkinsonism,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Syncope,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Skin reactions,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Urinary tract infection,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Urinary incontinence,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Sweating,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Atrial fibrillation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,AV block,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Depression,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Aggression,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Extrapyramidal symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Gastric and duodenal ulceration,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Pancreatitis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Angina,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Seizures,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Dehydration,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Hallucinations,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Hepatitis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Restlessness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Sick sinus syndrome,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Tachycardia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Hypertension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Constipation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Hypertension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dyspnoea,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Headache,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Impaired balance,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Drowsiness,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Thrombosis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Heart failure,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Confusion,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Fatigue,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Hallucinations,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Abnormal gait,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Seizures,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Pancreatitis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Psychosis,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Depression,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Suicidal ideation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Extrapyramidal symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Weight gain,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Dyslipidaemia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Hyperprolactinaemia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Sedation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Sleep apnoea syndrome,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Anticholinergic effects,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Postural hypotension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Hypertension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Reduced seizure threshold,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Impaired glucose tolerance,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,QT interval prolongation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Stroke risk,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Venous thromboembolism (VTE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Neuroleptic malignant syndrome (NMS),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Pneumonia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Neutropenia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Abnormal liver function tests (LFTs),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Photosensitivity,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Skin and subcutaneous tissue disorders,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Diplopia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Misuse and abuse,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,104,DB00502,drug,Haloperidol,DrugBank,,,SideEffect,Restless legs syndrome,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Extrapyramidal symptoms,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Weight gain,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Dyslipidaemia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Hyperprolactinaemia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Sedation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Sleep apnoea syndrome,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Anticholinergic effects,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Postural hypotension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Hypertension,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Reduced seizure threshold,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Impaired glucose tolerance,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,QT interval prolongation,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Stroke risk,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Venous thromboembolism (VTE),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Neuroleptic malignant syndrome (NMS),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Pneumonia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Neutropenia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Abnormal liver function tests (LFTs),,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Photosensitivity,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Skin and subcutaneous tissue disorders,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Diplopia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Misuse and abuse,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_SIDE_EFFECT,,-113,DB00734,drug,Risperidone,DrugBank,,,SideEffect,Restless legs syndrome,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Cognitive Stimulation Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Reminiscence Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Behavioral Management,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_THERAPY,,,,Stage,Severe (MMSE <10),,,,Therapy,Music Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Cognitive Stimulation Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Reminiscence Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Behavioral Management,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Music Therapy,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
THERAPY_EFFECTIVENESS,,,,Therapy,Cognitive Stimulation Therapy,,,,Effectiveness,Improves memory attention and social interaction,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
THERAPY_EFFECTIVENESS,,,,Therapy,Reminiscence Therapy,,,,Effectiveness,Helps maintain long-term memory improves mood,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
THERAPY_EFFECTIVENESS,,,,Therapy,Behavioral Management,,,,Effectiveness,Reduces anxiety and agitation improves daily functioning,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
THERAPY_EFFECTIVENESS,,,,Therapy,Music Therapy,,,,Effectiveness,Improves mood reduces agitation provides positive emotions,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Severe cardiac arrhythmia,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Pregnancy and breastfeeding.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,"History of bradycardia, heart block, recurrent unexplained syncope.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Concurrent treatment with drugs that reduce heart rate.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Sick sinus syndrome or other supraventricular conduction abnormalities.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Susceptibility to peptic ulcers including concurrent nonsteroidal anti inflammatory (NSAID) use.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Asthma and chronic obstructive pulmonary disease (COPD).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Hepatic impairment. ,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome (NMS).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome (NMS).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Hypersensitivity to galantamine or to any of the excipients.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m²).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Severe hepatic impairment (Child-Pugh score greater than 9).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,People who have both significant renal and hepatic dysfunction.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Urinary outflow obstruction.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Gastrointestinal obstruction.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,During recovery from bladder or gastrointestinal surgery.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Pregnancy and breastfeeding.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Renal and hepatic impairment.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,QTc interval prolongation or taking drugs that prolong the QTc interval.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,"History of severe asthma, COPD, or pulmonary infection.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,History of seizures.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Pregnancy and breastfeeding.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Hepatic impairment.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Renal impairment.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Gastric or duodenal ulcers (or susceptibility to ulcers).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Sick sinus syndrome or conduction abnormalities.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,History of asthma or COPD.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,History of seizures.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Bladder outflow obstruction.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,"Pre-existing, or a family history of, QT interval prolongation.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Higher risk of developing torsade de pointes,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Severe hepatic impairment.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Severe renal impairment — memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m².,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,History of convulsions or predisposing factors for epilepsy. ,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Severe renal impairment,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,"Central nervous system depression, comatose states.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,"prolongation, concurrent use with drugs that prolong the QT interval, history of",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Uncorrected hypokalaemia.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Progressive supranuclear palsy.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Dementia with Lewy bodies.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Parkinson's disease.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Blood dyscrasias.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,"Cardiovascular disease — an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Conditions predisposing to seizures.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Depression.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Diabetes (may raise blood glucose).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Epilepsy.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,History of jaundice.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Myasthenia gravis.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Parkinsonʼs disease (may be exacerbated).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Photosensitization (may occur with higher dosages).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Prostatic hypertrophy.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Severe respiratory disease.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Susceptibility to angle-closure glaucoma,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Bradycardia.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Uncorrected electrolyte disturbances.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Family history of QTc-interval prolongation.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,History of heavy alcohol exposure.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Hyperthyroidism.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Hypotension (including orthostatic hypotension).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Prolactin-dependent tumours.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Prolactinaemia.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,104,DB00502,drug,Haloperidol,DrugBank,,,Phenotypes,Risk factors for stroke.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Hypersensitivity to risperidone or to any of the excipients.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Acute porphyrias.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Cataract surgery (risk of intra-operative floppy iris syndrome).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Dehydration.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Dementia with Lewy bodies.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Prolactin-dependent tumours.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Blood dyscrasias.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,"Cardiovascular disease — an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Conditions predisposing to seizures.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Depression.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Diabetes (may raise blood glucose).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Epilepsy.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,History of jaundice.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Myasthenia gravis.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Parkinsonʼs disease (may be exacerbated).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Photosensitization (may occur with higher dosages).,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Prostatic hypertrophy.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Severe respiratory disease.,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-113,DB00734,drug,Risperidone,DrugBank,,,Phenotypes,Susceptibility to angle-closure glaucoma,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
MONITORING_TREATMENT,,,,Treatment,Galantamine Treatment (NICE),,,,Monitoring,Weight monthly,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,初期,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,中期,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,晚期,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (成大),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (成大),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
TREATMENT_STEP,,,,Treatment,Donepezil Treatment (成大),,,,Step,Donepezil Treatment (成大) (1),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (成大) (1),,,,Dosage,Donepezil 5 mg/day,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 5mg/day,,,,Duration,4-6 week,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_STEP,,,,Step,Donepezil Treatment (成大) (1),,,,Step,Donepezil Treatment (成大) (2),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (成大) (2),,,,Dosage,Donepezil 5-10 mg/day,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Treatment (NICE),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (成大),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (成大),,,,Dosage,Rivastigmine 1.5-6mg/day*2,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Galantamine  Treatment (NICE),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (成大),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
TREATMENT_STEP,,,,Treatment,Galantamine Treatment (成大),,,,Step,Galantamine Treatment (成大) (1),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_DOSAGE,,,,Step,Galantamine Treatment (成大) (1),,,,Dosage,Galantamine 4mg/day*2,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_STEP,,,,Step,Galantamine Treatment (成大) (1),,,,Step,Galantamine Treatment (成大) (2),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
STEP_DOSAGE,,,,Step,Galantamine Treatment (成大) (2),,,,Dosage,Galantamine 16-24mg/day,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (NICE),,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (成大),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment (成大),,,,Dosage,Memantine 5-20mg/day,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Nausea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Insomnia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Vomiting,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Muscle cramps,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Fatigue,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,decreased appetite,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Headache,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Dizziness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Anxiety,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Nausea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Diarrhea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Insomnia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Vomiting,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Depressed,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine patch,,,,SideEffect,Dyspepsia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Nausea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Anorexia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Nausea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Anorexia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Drowsiness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Anorexia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dyspepsia,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Weight lose,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Headache,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Drowsiness,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Hallucination,,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Myalgia,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Mild (MMSE 21-26),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Moderate (MMSE 10-20),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Severe (MMSE <10),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Mild  (ADAS-Cog),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Moderate (ADAS-Cog),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Severe (ADAS-Cog),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Mild  (ADAS-Cog),,,,Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Phenotypes,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Moderate (ADAS-Cog),,,,Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Phenotypes,Fully dependent,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_PHENOTYPES,,,,Stage,Severe (ADAS-Cog),,,,Phenotypes,Fully dependent,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild  (ADAS-Cog),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild  (ADAS-Cog),,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild  (ADAS-Cog),,,,Treatment,Rivastigmine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild  (ADAS-Cog),,,,Treatment,Galantamine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Galantamine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (ADAS-Cog),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (ADAS-Cog),,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (ADAS-Cog),,,,Treatment,Rivastigmine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Moderate (ADAS-Cog),,,,Treatment,Galantamine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Severe (ADAS-Cog),,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_TREATMENT,,,,Stage,Severe (ADAS-Cog),,,,Treatment,Memantine Treatment (MaHTAS),,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment  (MaHTAS),,,,Evidence,Moderate quality (Level B),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,,,Evidence,Moderate quality (Level B),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (MaHTAS),,,,Evidence,Moderate quality (Level B),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment (MaHTAS),,,,Evidence,Moderate quality (Level B),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment (MaHTAS),,,,Evidence,Moderate to Low quality,,SR,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (MaHTAS),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_DOSAGE,,,,Treatment,Donepezil Treatment (MaHTAS),,,,Dosage,Donepezil 10 mg/day,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10 mg/day,,,,Duration,12-24 week,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (MaHTAS),,,,Population,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (MaHTAS),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (MaHTAS),,,,Dosage,Rivastigmine 6 - 12 mg/day*2,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 6 - 12 mg/day*2,,,,Duration,26 week,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (MaHTAS),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,,,Dosage,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 9.5 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,,,Population,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (MaHTAS),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_DOSAGE,,,,Treatment,Galantamine Treatment (MaHTAS),,,,Dosage,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DOSAGE_DURATION,,,,Treatment,Galantamine Treatment (MaHTAS),,,,Duration,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (MaHTAS),,,,Population,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (MaHTAS),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (MaHTAS),,,,Population,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Exercise,,,,Effectiveness,Rivastigmine,,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Diet and supplement,,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2021-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2006-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2006-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2006-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://jamanetwork.com/journals/jama/fullarticle/1810379#google_vignette,2014-01-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),,,,Evidence,Rivastigmine,,SR,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 5mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 1.5 mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 3 mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 4.5 mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,,,
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8 mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8 mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 5mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 5mg/day*2,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 10mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 5mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 7 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 14 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 14 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 21 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (5),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_TREATMENT,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_STEP,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 7 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,"Vitamin E 1,000IU/day*2",,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 14 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,"Vitamin E 1,000IU/day*2",,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 14 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,"Vitamin E 1,000IU/day*2",,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Memantine 21 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,Donepezil 10mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DOSAGE_DURATION,,,,Dosage,"Vitamin E 1,000IU/day*2",,,,Duration,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_STEP,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),,,,Step,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
STEP_DOSAGE,,,,Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),,,,Dosage,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
TREATMENT_POPULATION,,,,Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),,,,Population,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017-01-01
DRUG_SIDE_EFFECT,,-26,DB00163,drug,Vitamin E,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p772.pdf,2017-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://cks.nice.org.uk/topics/dementia/,2024-04-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p773.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p774.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p775.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Mild (MMSE 21-26),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p776.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p777.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p778.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p779.pdf,2017-01-01
STAGE_THERAPY,,,,Stage,Moderate (MMSE 10-20),,,,Therapy,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p780.pdf,2017-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Enjoyable leisure activities,,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p781.pdf,2017-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Mental stimulation programs,,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p782.pdf,2017-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Occupational therapy training in coping strategies and cognitive aides,,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p783.pdf,2017-01-01
THERAPY_EFFECTIVENESS,,,,Therapy,Structured physical exercise programs,,,,Effectiveness,Rivastigmine,,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p784.pdf,2017-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,早期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,早期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,早期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,早期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,早期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,中期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,中期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,中期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,中期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,中期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,晚期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,晚期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,晚期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,晚期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_PHENOTYPES,,,,Stage,晚期,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_STEP,,,,Treatment,Donepezil Treatment (臺中榮總),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Donepezil Treatment (臺中榮總) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Donepezil 5 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Donepezil Treatment (臺中榮總) (1),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Donepezil Treatment (臺中榮總) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_EFFECTIVENESS,,,,Treatment,Donepezil Treatment (臺中榮總),,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_STEP,,,,Treatment,Rivastigmine Treatment (臺中榮總),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (臺中榮總) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Rivastigmine 1.5 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Rivastigmine Treatment (臺中榮總) (1),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (臺中榮總) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Rivastigmine 1.5 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Rivastigmine Treatment (臺中榮總) (2),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Rivastigmine Treatment (臺中榮總) (3),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Rivastigmine Patch Treatment (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_STEP,,,,Treatment,Rivastigmine Patch Treatment (臺中榮總),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (臺中榮總) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 4.6 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Rivastigmine Patch Treatment (臺中榮總) (1),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Rivastigmine Patch Treatment (臺中榮總) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Patch Treatment (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_STEP,,,,Treatment,Galantamine Treatment (臺中榮總),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Galantamine Treatment (臺中榮總) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 4.6 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Galantamine Treatment (臺中榮總) (1),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Galantamine Treatment (臺中榮總) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_STEP,,,,Treatment,Memantine Treatment (臺中榮總),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Memantine Treatment (臺中榮總) (1),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DOSAGE_DURATION,,,,Dosage,Rivastigmine Patch 4.6 mg/day,,,,Duration,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_STEP,,,,Step,Memantine Treatment (臺中榮總) (1),,,,Step,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STEP_DOSAGE,,,,Step,Memantine Treatment (臺中榮總) (2),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment (臺中榮總),,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_TREATMENT,,,,Treatment,Memantine Treatment 腎功能不佳者 (臺中榮總),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_DOSAGE,,,,Step,Memantine Treatment 腎功能不佳者 (臺中榮總),,,,Dosage,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment 腎功能不佳者 (臺中榮總),,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment 腎功能不佳者 (臺中榮總),,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment 腎功能不佳者 (臺中榮總),,,,Population,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,,,drug,Rivastigmine Patch,,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Reminiscence Therapy,,,,THERAPY_EFFECTIVENESS,Rivastigmine,,Sensory Stimulation,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Cognitive Activities,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Music Therapy Groups,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Art Creation,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Exercise Groups,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Reality Orientation Therapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Dance Therapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Horticulture Therapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Aromatherapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Pet Therapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Doll Therapy,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
THERAPY_EFFECTIVENESS,,,,Therapy,Sensory Stimulation,,,,Effectiveness,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00843,drug,Donepezil,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,22,DB00989,drug,Rivastigmine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,,,drug,Rivastigmine Patch,,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,9,DB00674,drug,Galantamine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Phenotypes,Rivastigmine,,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023-04-21
STAGE_TREATMENT,,,,Stage,Early stage(GDS 2-5),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(GDS 2-5),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(GDS 2-5),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (GDS 4-6),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (GDS 4-6),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (GDS 4-6),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (GDS 4-6),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Treatment,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(GDS 2-5),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (GDS 4-6),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (GDS 7),,,,Phenotypes,Rivastigmine,,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024-01-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment (MaHTAS),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Patch Treatment (MaHTAS),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (MaHTAS),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment (MaHTAS),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),,,,Evidence,Rivastigmine,,SR,https://academic.oup.com/ijnp/article/18/5/pyu115/786398?login=false,2017-07-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment (MaHTAS),,,,Evidence,Rivastigmine,,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (Japanese Society of Neurology),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Donepezil Treatment (Japanese Society of Neurology),,,,Dosage,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (Japanese Society of Neurology),,,,Population,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (Japanese Society of Neurology),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Galantamine Treatment (Japanese Society of Neurology),,,,Dosage,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (Japanese Society of Neurology),,,,Population,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (Japanese Society of Neurology),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (Japanese Society of Neurology),,,,Dosage,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (Japanese Society of Neurology),,,,Population,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),,,,Dosage,Rivastigmine Patch 9.5 mg/day,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (Japanese Society of Neurology),,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (Japanese Society of Neurology),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment (Japanese Society of Neurology),,,,Dosage,Memantine 20 mg/day,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (Japanese Society of Neurology),,,,Population,Moderate to severe Alzheimer's Disease (MMSE < 20),,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DRUG_TREATMENT,,,,Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),,,,Dosage,Memantine 28 mg/day,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_DOSAGE,,,,Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),,,,Dosage,Donepezil 5-10 mg/day,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (Japanese Society of Neurology),,,,Population,Moderate to severe Alzheimer's Disease (MMSE < 20),,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Exercise therapy,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Music therapy,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
THERAPY_EVIDENCE_LEVEL,,,,Therapy,Exercise therapy,,,,Evidence,Low quality (Level C),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006489.pub4/full,2017-07-01
THERAPY_EVIDENCE_LEVEL,,,,Therapy,Music therapy,,,,Evidence,Low quality (Level C),,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003477.pub2/full,2017-07-01
THERAPY_EFFECTIVENESS,,,,Therapy,Exercise therapy,,,,Effectiveness,attenuates worsening of physical function and activities of daily living,,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
THERAPY_EFFECTIVENESS,,,,Therapy,Music therapy,,,,Effectiveness,"improving BPSD, including anxiety",,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017-07-01
STAGE_TREATMENT,,,,Stage, (MCI) due to Alzheimer's disease,,,,Treatment,Donanemab Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage, (MCI) due to Alzheimer's disease,,,,Treatment,Lecanemab (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Suvorexant,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Donanemab Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Lecanemab (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Donepezil Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Rivastigmine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Early stage(mild),,,,Treatment,Galantamine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Suvorexant,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Donepezil Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Rivastigmine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Galantamine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Memantine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Middle stage (moderate),,,,Treatment,Memantine + Donepezil (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (severe),,,,Treatment,Donepezil Treatment (Alzheimer Society of B.C.),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (severe),,,,Treatment,Memantine Treatment (Alzheimer Society of B.C.),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage,Late stage (severe),,,,Treatment,Memantine + Donepezil (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage, MCI due to Alzheimer's disease,,,,Phenotypes,memory loss ,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_TREATMENT,,,,Stage, MCI due to Alzheimer's disease,,,,Phenotypes,cognitive ability loss,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Difficultly coming up with the right word or name.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Difficultly remembering names when introduced to new people.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Having difficulty performing tasks in social or work settings.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Forgetting material that was just read.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Losing or misplacing a valuable object.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Early stage(mild),,,,Phenotypes,Experiencing increased trouble with planning or organizing.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,Being forgetful of events or personal history.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,Experiencing confusion about where they are or what day it is.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,Requiring help choosing proper clothing for the season or the occasion.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,Having trouble controlling their bladder and bowels.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,Showing an increased tendency to wander and become lost.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Middle stage (moderate),,,,Phenotypes,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Late stage (severe),,,,Phenotypes,Require around-the-clock assistance with daily personal care.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Late stage (severe),,,,Phenotypes,Lose awareness of recent experiences as well as of their surroundings.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Late stage (severe),,,,Phenotypes,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Late stage (severe),,,,Phenotypes,Have difficulty communicating.,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
STAGE_PHENOTYPES,,,,Stage,Late stage (severe),,,,Phenotypes,"Become vulnerable to infections, especially pneumonia.",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donanemab Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Donanemab Treatment (Alzheimer's Association),Guideline,,,drug,Donanemab,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Donanemab Treatment (Alzheimer's Association),,,,Population, MCI to Mild Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Lecanemab (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Lecanemab (Alzheimer's Association),Guideline,,,drug,Lecanemab,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Lecanemab (Alzheimer's Association),,,,Population, MCI to Mild Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (Alzheimer's Association),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (Alzheimer's Association),,,,Population,Mild to severe Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (Alzheimer's Association),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (Alzheimer's Association),,,,Population,Mild to moderate Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Galantamine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (Alzheimer's Association),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (Alzheimer's Association),,,,Population,Mild to moderate Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (Alzheimer's Association),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (Alzheimer's Association),,,,Population,Moderate to severe Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine + Donepezil (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Memantine + Donepezil (Alzheimer's Association),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Memantine + Donepezil (Alzheimer's Association),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Memantine + Donepezil (Alzheimer's Association),,,,Population,Moderate to severe Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Brexpiprazole Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Brexpiprazole Treatment (Alzheimer's Association),Guideline,,,drug,Brexpiprazole,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Brexpiprazole Treatment (Alzheimer's Association),,,,Population,Agitation associated with dementia due to Alzheimer's disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Suvorexant Treatment (Alzheimer's Association),,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_TREATMENT,,,,Treatment,Suvorexant Treatment (Alzheimer's Association),Guideline,,,drug,Suvorexant,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Suvorexant Treatment (Alzheimer's Association),,,,Population,Insomnia,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
TREATMENT_POPULATION,,,,Treatment,Suvorexant Treatment (Alzheimer's Association),,,,Population,Mild to moderate Alzheimer's Disease,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,,drug,Donanemab,Guideline,,,SideEffect,ARIA,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,,drug,Donanemab,Guideline,,,SideEffect,headache,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-93,DB14580,drug,Lecanemab,DrugBank,,,SideEffect,Infusion-related reactions,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-93,DB14580,drug,Lecanemab,DrugBank,,,SideEffect,ARIA,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-93,DB14580,drug,Lecanemab,DrugBank,,,SideEffect,headache,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Nausea,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Vomiting,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Loss of appetite,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Muscle cramps,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Increased frequency of bowel movements,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Nausea,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Loss of appetite,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Increased frequency of bowel movements,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Nausea,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Vomiting,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Loss of appetite,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Increased frequency of bowel movements,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,headache,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Constipation,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Confusion,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,DB09128,drug,Brexpiprazole,DrugBank,,,SideEffect,Weight gain,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,DB09128,drug,Brexpiprazole,DrugBank,,,SideEffect,Sleepiness,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,DB09128,drug,Brexpiprazole,DrugBank,,,SideEffect,Dizziness,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,DB09128,drug,Brexpiprazole,DrugBank,,,SideEffect,Common cold symptoms,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,,DB09128,drug,Brexpiprazole,DrugBank,,,SideEffect,Restlessness or feeling like  need to move,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-5,DB09034,drug,Suvorexant,DrugBank,,,SideEffect,Impaired alertness and motor coordination,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-5,DB09034,drug,Suvorexant,DrugBank,,,SideEffect,Worsening of depression or suicidal thinking,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-5,DB09034,drug,Suvorexant,DrugBank,,,SideEffect,Complex sleep behaviors,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-5,DB09034,drug,Suvorexant,DrugBank,,,SideEffect,Sleep paralysis,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DRUG_SIDE_EFFECT,,-5,DB09034,drug,Suvorexant,DrugBank,,,SideEffect,Compromised respiratory function,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Maintain regular times for meals and for going to bed and getting up,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Seek morning sunlight exposure,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,"Encourage regular daily exercise, but no later than four hours before bedtime",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,"Avoid alcohol, caffeine and nicotine",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Treat any pain,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Make sure the bedroom temperature is comfortable,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Provide nightlights and security objects,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_THERAPY,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Therapy,Discourage watching television during periods of wakefulness,,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024-01-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Mild (MMSE 21-26),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Moderate (MMSE 10-20),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Severe (MMSE <10),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Memory loss for recent events,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Difficulty learning new information,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Subtle language problems,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Significant memory loss,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Confusion in daily activities,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Behavioral changes,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Severe memory loss,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Complete dependence on others,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Physical symptoms,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Donepezil Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Donepezil Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Memantine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment (Demenzen),,,,Evidence,Moderate quality (Level B),,SR,https://www.dgppn.de/_Resources/Persistent/1f641e4edaf5c5d5a5114ee69146ba459a7da6b3/S3-Leitlinie%20Demenzen_Langversion_2023_11_28_Final%20(003).pdf,2023-11-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (Demenzen),,,,Evidence,Moderate quality (Level B),,SR,https://www.dgppn.de/_Resources/Persistent/1f641e4edaf5c5d5a5114ee69146ba459a7da6b3/S3-Leitlinie%20Demenzen_Langversion_2023_11_28_Final%20(003).pdf,2023-11-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment (Demenzen),,,,Evidence,Moderate quality (Level B),,SR,https://www.dgppn.de/_Resources/Persistent/1f641e4edaf5c5d5a5114ee69146ba459a7da6b3/S3-Leitlinie%20Demenzen_Langversion_2023_11_28_Final%20(003).pdf,2023-11-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment (Demenzen),,,,Evidence,Moderate quality (Level B),,SR,https://pubmed.ncbi.nlm.nih.gov/30891742/,2023-11-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023-11-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (Demenzen),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_2.pdf,2023-11-01
TREATMENT_DOSAGE,,,,Treatment,Donepezil Treatment (Demenzen),,,,Dosage,Donepezil 5mg/day,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_3.pdf,2023-11-01
DOSAGE_DURATION,,,,Dosage,Donepezil 5mg/day,,,,Duration,1 month,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_4.pdf,2023-11-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Donepezil Treatment (Demenzen),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_5.pdf,2023-11-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (Demenzen),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_6.pdf,2023-11-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Galantamine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_8.pdf,2023-11-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (Demenzen),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_9.pdf,2023-11-01
TREATMENT_DOSAGE,,,,Treatment,Galantamine Treatment (Demenzen),,,,Dosage,Galantamine 8mg/day,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_10.pdf,2023-11-01
DOSAGE_DURATION,,,,Dosage,Galantamine 8mg/day,,,,Duration,1 month,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_11.pdf,2023-11-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Galantamine Treatment (Demenzen),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_12.pdf,2023-11-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (Demenzen),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_13.pdf,2023-11-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_15.pdf,2023-11-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (Demenzen),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_16.pdf,2023-11-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment (Demenzen),,,,Dosage,Memantine 5mg/day,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_17.pdf,2023-11-01
DOSAGE_DURATION,,,,Treatment,Memantine Treatment (Demenzen),,,,Duration,Review every 6 months,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_18.pdf,2023-11-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment (Demenzen),,,,Effectiveness,significant effect on ADL function at 24 weeks,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_19.pdf,2023-11-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (Demenzen),,,,Population,Moderate to severe Alzheimer's Disease (MMSE < 20),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_20.pdf,2023-11-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Treatment (Demenzen),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_22.pdf,2023-11-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (Demenzen),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_23.pdf,2023-11-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (Demenzen),,,,Dosage,Rivastigmine 3mg/day,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_24.pdf,2023-11-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 3mg/day,,,,Duration,2 weeks,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_25.pdf,2023-11-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Rivastigmine Treatment (Demenzen),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_26.pdf,2023-11-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (Demenzen),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_27.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Nausea,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_29.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Vomiting,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_30.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_31.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Headache,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_32.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Dizziness,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_33.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Agitation,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_34.pdf,2023-11-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Gastrointestinal,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_35.pdf,2023-11-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Agitation,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_36.pdf,2023-11-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Hypertension,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_37.pdf,2023-11-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Falls,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_38.pdf,2023-11-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_39.pdf,2023-11-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Headache,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_40.pdf,2023-11-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Gastrointestinal,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_41.pdf,2023-11-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_42.pdf,2023-11-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Headache,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_43.pdf,2023-11-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Condition,Severe renal impairment,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_45.pdf,2023-11-01
MONITORING_TREATMENT,,,,Treatment,Donepezil Treatment (Demenzen),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_47.pdf,2023-11-01
MONITORING_TREATMENT,,,,Treatment,Memantine Treatment (Demenzen),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_48.pdf,2023-11-01
MONITORING_TREATMENT,,,,Treatment,Rivastigmine Treatment (Demenzen),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_49.pdf,2023-11-01
MONITORING_TREATMENT,,,,Treatment,Galantamine Treatment (Demenzen),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_50.pdf,2023-11-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Mild (MMSE 21-26),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Moderate (MMSE 10-20),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DISEASES_STAGE,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Stage,Severe (MMSE <10),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Memory loss for recent events,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Difficulty learning new information,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Mild (MMSE 21-26),,,,Symptom,Subtle language problems,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Significant memory loss,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Confusion in daily activities,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Moderate (MMSE 10-20),,,,Symptom,Behavioral changes,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Severe memory loss,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Complete dependence on others,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_PHENOTYPES,,,,Stage,Severe (MMSE <10),,,,Symptom,Physical symptoms,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Donepezil Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Rivastigmine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Donepezil Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Moderate (MMSE 10-20),,,,Treatment,Memantine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Mild (MMSE 21-26),,,,Treatment,Galantamine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
STAGE_TREATMENT,,,,Stage,Severe (MMSE <10),,,,Treatment,Memantine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Donepezil Treatment (CDPC),,,,Evidence,Low quality (Level C),,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016-02-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Rivastigmine Treatment (CDPC),,,,Evidence,Moderate quality (Level B),,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016-02-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Galantamine Treatment (CDPC),,,,Evidence,Moderate quality (Level B),,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016-02-01
TREATMENT_EVIDENCE_LEVEL,,,,Treatment,Memantine Treatment (CDPC),,,,Evidence,Moderate quality (Level B),,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016-02-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Donepezil Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_TREATMENT,,,,Treatment,Donepezil Treatment (CDPC),Guideline,15126,DB00843,drug,Donepezil,DrugBank,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_DOSAGE,,,,Treatment,Donepezil Treatment (CDPC),,,,Dosage,Donepezil 5mg/day,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DOSAGE_DURATION,,,,Dosage,Donepezil 5mg/day,,,,Duration,Review every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Donepezil Treatment (CDPC),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_POPULATION,,,,Treatment,Donepezil Treatment (CDPC),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Galantamine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_TREATMENT,,,,Treatment,Galantamine Treatment (CDPC),Guideline,15113,DB00674,drug,Galantamine,DrugBank,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_DOSAGE,,,,Treatment,Galantamine Treatment (CDPC),,,,Dosage,Galantamine 5mg/day,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DOSAGE_DURATION,,,,Dosage,Galantamine 5mg/day,,,,Duration,Review every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Galantamine Treatment (CDPC),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_POPULATION,,,,Treatment,Galantamine Treatment (CDPC),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Memantine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_TREATMENT,,,,Treatment,Memantine Treatment (CDPC),Guideline,-54,DB01043,drug,Memantine,DrugBank,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_DOSAGE,,,,Treatment,Memantine Treatment (CDPC),,,,Dosage,Memantine 5mg/day,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DOSAGE_DURATION,,,,Dosage,Memantine 5mg/day,,,,Duration,Review every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Memantine Treatment (CDPC),,,,Effectiveness,significant effect on ADL function at 24 weeks,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_POPULATION,,,,Treatment,Memantine Treatment (CDPC),,,,Population,Moderate to severe Alzheimer's Disease (MMSE < 20),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DISEASES_TREATMENT,,28780,11913_7088_11743_12153_7089_11194_12321_15140_4975_11561_11647_11777_12344_12609_12630_12631_14265_10422_14036_14316_100088,disease,Alzheimer disease,MONDO_grouped,,,Treatment,Rivastigmine Treatment (CDPC),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_TREATMENT,,,,Treatment,Rivastigmine Treatment (CDPC),Guideline,17174,DB00989,drug,Rivastigmine,Guideline,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_DOSAGE,,,,Treatment,Rivastigmine Treatment (CDPC),,,,Dosage,Rivastigmine 5mg/day,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DOSAGE_DURATION,,,,Dosage,Rivastigmine 5mg/day,,,,Duration,Review every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_EFFECTIVENESS,,,,Treatment,Rivastigmine Treatment (CDPC),,,,Effectiveness,small significant benefit on cognitive function and ADL,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
TREATMENT_POPULATION,,,,Treatment,Rivastigmine Treatment (CDPC),,,,Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Nausea,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Vomiting,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Diarrhea,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Headache,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Dizziness,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00843,drug,Donepezil,DrugBank,,,SideEffect,Agitation,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,22,DB00989,drug,Rivastigmine,DrugBank,,,SideEffect,Gastrointestinal,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Agitation,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Hypertension,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Falls,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,-54,DB01043,drug,Memantine,DrugBank,,,SideEffect,Headache,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Gastrointestinal,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Dizziness,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_SIDE_EFFECT,,9,DB00674,drug,Galantamine,DrugBank,,,SideEffect,Headache,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
DRUG_PHENOTYPES_CONTRAINDICATION,,-54,DB01043,drug,Memantine,DrugBank,,,Condition,Severe renal impairment,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
MONITORING_TREATMENT,,,,Treatment,Donepezil Treatment (CDPC),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
MONITORING_TREATMENT,,,,Treatment,Memantine Treatment (CDPC),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
MONITORING_TREATMENT,,,,Treatment,Rivastigmine Treatment (CDPC),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
MONITORING_TREATMENT,,,,Treatment,Galantamine Treatment (CDPC),,,,Monitoring,Cognitive function (MMSE) every 6 months,,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016-02-01
